Assessment of tissue estrogen and progesterone receptor levels: A survey of current practice, techniques, and quantitation methods

Breast Journal

Volumn 6, Issue 3, 2000, Pages 189-196

  Layfield, Lester J ^a   Gupta, Dilip ^a   Mooney, Eoghan E ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Breast carcinoma; Estrogen receptor; Progesterone receptor; Steroid hormone assay

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CLINICAL LABORATORY; CONTROLLED STUDY; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; QUALITY CONTROL;

EID: 0034036326     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2000.99097.x     Document Type: Article

References (24)

1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
2. Allegra JC, Lippman MC, Thompson EB, et al. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer 1980;16:323-31.
3. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Marrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996:461-85.
4. Henson JC, Longeval E, Mattheiem WH, Deboel MC, Sylvester RJ, Leclercq G. Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer 1977;39:1971-77.
5. Campbell FC, Blamey RW, Elston CW, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981;2: 1317-19.
6. McCarty KS Jr, Miller LS, Cox EB, Keonrath J, McCarty KSS. Estrogen receptor analysis. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109:716-21.
7. Sondergaard G, Pedersen KO, Paulsen SM. Estrogen receptor analyses in breast cancer: comparison of monoclonal immunohistochemical and biochemical methods. Eur J Cancer Clin Oncol 1989;25:1425-29.
8. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989;49:1052-56.
9. Pertschuk LP, Kim DS, Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies: histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990;66:1663-70.
10. Kell DL, Kamel OW, Rouse RV. Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue. Correlation of clones ERID5 and IA6 with a cytosol-based hormone receptor assay. Appl Immunohistochem 1993;1:275-81.
11. Esteban JM, Kandalaft PL, Mehta P, Odom-Maryon TL, Bacus S, Battifora H. Improvement on the quantification of estrogen and progesterone receptors on paraffin-embedded tumors by image analysis. Am J Clin Pathol 1993;99:32-38.
12. Layfield LJ, Conlon DH, Dodge R, Saria E, Kerns BJ. Immunohistochemically determined estrogen and progesterone receptor levels: a comparison of three commercially available antibodies with the ligand-binding assay. Breast J 1996;2:362-71.
13. Mauri FA, Veronese S, Frigo B, et al. ERIDS and H222 (ER-ICA) antibodies to human estrogen receptor protein in breast carcinoma: results of a multicentric comparative study. Appl Immunohistochem. 1994;2:157-63.
14. Esteban JM, Ahn C, Mehta P, Battifora H. Biological significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer patients. Am J Clin Pathol 1994;102:158-62.
15. Andersen J, Poulson HS. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989;64:1901-8.
16. Pertschuk LP, Feldman JG, Eisenberg KB, et al. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease free survival and clinical endocrine response. Cancer 1988;62:342-49.
17. Harvey JM, Clark GM, Osborne K, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
18. Riera J, Simpson JF, Tamayo R, Battifora H. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. Am J Clin Pathol 1999;111:329-35.
19. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer 1998;78:16-20.
20. Hudis CA, Norton L. Adjuvant drug therapy for operable breast cancer. Semin Oncol 1996;23:475-93.
21. Rutquist LE, Hatschek T, Ryden S, et al. Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early stage breast cancer. J Natl Cancer Inst 1996; 88:1543-49.
22. Thorpe S, Christensen IJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of post menopausal, primary breast cancer. Eur J Cancer 1993;29A:971-77.
23. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980;16:1513-15.
24. Cramer SF. Interobserver variability in surgical pathology. Adv Pathol and Lab Med 1996;6:3-82.